Metastatic Prostate Cancer Epidemiology Forecast to 2030 by DelveInsight - The Daily Chronicle

(Albany, US) DelveInsight has launched a new report on Metastatic Prostate Cancer Epidemiology

DelveInsight’s ‘Metastatic Prostate Cancer Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Metastatic Prostate Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Prostate cancer starts in the prostate gland–and is the second most common form of cancer in men. The cancer spreads, or metastasized, from the prostate to other areas of the body with the help of blood stream or lymphatic system, which results in the metastasis of tumor, leading to the development of Advanced Prostate Cancer. Castration-resistant prostate cancer is defined by a rising prostate-specific antigen (PSA) level and/or worsening symptoms and/or growing cancer verified by scans. If the cancer has not spread to other parts of the body, it is called “non-metastatic castration-resistant prostate cancer (nmCRPC)” and if it is spread to other parts of the body called as “-metastatic castration-resistant prostate cancer (mCRPC).” (ASCO; cancer net).

View free sample page: – https://ift.tt/3lh969y

Metastatic Prostate Cancer Epidemiology

Metastatic Prostate cancer is the most frequently diagnosed cancer and the third leading cause of cancer deaths in males. It is associated with significant morbidity, including pain, pathologic fractures, spinal cord compression and bone marrow failure. As per the Cancer Research UK, among the diagnosed prostate cancer cases in England, Scotland, 17% and 34% of prostate cancer patients have metastases at diagnosis (stage IV). It is found to be more common in the adults aged (39%) than the younger persons (30%).

Key facts of the report

• According to NCI, 164,690 new cases were reported in the USA in 2018 and with an estimated 29,430 deaths in the US for 2017. Approximately 6% of new PCA cases present with metastasis, with a 5–yr. survival rate of 28.2%. The risk is increased with old age, positive family history, and other factors such as traditional socioeconomic, clinical, and pathologic factors.
• According to Global cancer statistics 2012, the incidence of prostate cancer in Japan is rapidly increasing, even though it is still much lower than in Western populations. The study by Inoue et al., reported that in a population of 151 patients with CRPC, 84% had bone metastases at diagnosis.
• The majority incident cases of mCRPC were recorded in the United States.
• Based on UK primary care database analysis, 11,600 castrated prostate cancer cases were identified for study period of 1999–2009. Of these, 28% developed CRPC during the study period, with an incidence rate of 8.3 per 100 person years in CRPC, and 3.8 per 100 person years in all prostate cancer patients.
• The lowest incident population of mCRPC was recorded in Japan.

Metastatic Prostate Cancer Report Scope

• The Metastatic Prostate Cancer report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Metastatic Prostate Cancer Epidemiology Report and Model provide an overview of the risk factors and global trends of Metastatic Prostate Cancer in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Metastatic Prostate Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Metastatic Prostate Cancer
• The report provides the segmentation of the Metastatic Prostate Cancer epidemiology

Download free sample page: – https://ift.tt/3lh969y

Table of content

1. Key Insights
2. Executive Summary of Metastatic Prostate Cancer
3. Metastatic Prostate Cancer: Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
9. Appendix
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight

Why should you buy this report?

The Metastatic Prostate Cancer Epidemiology report will allow the user to –

• Develop business strategies by understanding the trends shaping and driving the global Metastatic Prostate Cancer market
• Quantify patient populations in the global Metastatic Prostate Cancer market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Metastatic Prostate Cancer therapeutics in each of the markets covered
• Understand the magnitude of Metastatic Prostate Cancer population by its epidemiology
• The Metastatic Prostate Cancer Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Related Reports